Lack of evidence for cancer due to use of metronidazole.
about
Clinical and microbiological aspects of Trichomonas vaginalisVaginitis: current microbiologic and clinical conceptsThe biology of Giardia sppTreatment of anaerobic infectionMetronidazole excretion in human milk and its effect on the suckling neonateNonhormonal drugs and cancerAssessment of office-based care of sexually transmitted diseases and vaginitis and antibiotic decision-making by obstetrician-gynecologists.Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.Investigation of metronidazole use during pregnancy and adverse birth outcomes.Review of vaginitis.Comparative study of intravaginal metronidazole and triple-sulfa therapy for bacterial vaginosis.Amebiasis: clinical and laboratory perspectives.Antianaerobic antimicrobials: spectrum and susceptibility testing.Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity.Antimicrobial treatment of anaerobic infections.Industrial risk factors for colorectal cancer.Antimicrobials therapy of anaerobic infections.Surgical antimicrobial prophylaxis: principles and guidelines.Treatment of giardiasis: literature review and recommendations.The association of inflammatory bowel disease and leukemia--coincidence or not?Management of recalcitrant Trichomonas vaginalis in pregnancy: a case report.Chemical constituents of Osyris alba and their antiparasitic activities.Treatment of giardiasis.
P2860
Q24520495-8F052609-9305-4D9A-8196-12912D98D631Q24550032-E41E6BC9-ECBB-4A58-9EAD-579D8FE8F2E4Q24634708-EA5EF211-590B-4CAF-8CA0-1C68616F5242Q28258687-FEC6C1EB-8364-44AD-B4A1-95C0B1252CF9Q34417745-D8AB9265-7F13-4044-B029-CBAD060DE260Q34833625-56B64865-BAC2-473C-A4F8-511B0624E410Q35615584-61AA70D9-001A-48CD-BA95-C3437F306B02Q35690192-789C30A0-F36A-450B-A814-48740AB41A0CQ36172432-25DB0622-4209-4527-834E-75DF6F00CB46Q36624336-36E2C53D-C0BC-4ED1-97D7-EB1B6E6A081AQ36625018-9335C8F8-9D42-46DE-B89A-684FB8847367Q36921709-819775D9-6A8F-4F18-BB69-5F1188F70FE2Q37035824-891D3923-01D0-44AF-B243-6FF5FAC276BBQ37381789-B52579F4-F300-4AFB-880E-22598C5EBBD8Q37867124-4A5CED84-C94C-41C9-AF37-B83B6A225CE8Q37946911-BEA5F988-80AD-4A9C-8EA7-D12493BB58F4Q38586018-D7B0E39B-D356-4BC3-A58F-0968836978EEQ40214971-30B96482-F1CF-40A6-8C99-B99BB701E45AQ40331955-01703AFC-F0A6-4F2B-A90A-36580C70E007Q40958104-A48DE02A-CD2B-4DE3-B929-3643E3B911FDQ41364999-810B373F-DC3E-43EE-B0C1-79879A5CC40BQ42908210-23972536-B8F6-450A-BBE0-C2D25F11A84DQ55034504-8A26DDBC-3FAD-4B0C-A804-81EA4545DC9D
P2860
Lack of evidence for cancer due to use of metronidazole.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
Lack of evidence for cancer due to use of metronidazole.
@en
type
label
Lack of evidence for cancer due to use of metronidazole.
@en
prefLabel
Lack of evidence for cancer due to use of metronidazole.
@en
P2093
P1476
Lack of evidence for cancer due to use of metronidazole.
@en
P2093
Dockerty MB
Kurland LT
O'Fallon WM
P304
P356
10.1056/NEJM197909063011003
P407
P577
1979-09-01T00:00:00Z